Glaukos price target lowered to $135 from $140 at Truist

Truist analyst Richard Newitter lowered the firm’s price target on Glaukos (GKOS) to $135 from $140 but keeps a Buy rating on the shares. The company’s Q1 is unlikely to ‘re-validate’ the bull-case iDose ramp, but the firm still believes that it’s a matter of “when, not if,” that validation is nearing, the analyst tells investors in a research note. Coverage progress highlighted on the earnings call points to a higher level of visibility into a steepening iDose trajectory, the firm adds.